Use of zoledronic acid for treatment of chemotherapy related osteonecrosis in children and adolescents: A retrospective analysis

Pediatric Blood and Cancer

Volumn 60, Issue 9, 2013, Pages 1539-1545

  Padhye, Bhavna ^a   Dalla Pozza, Luciano ^a   Little, David G ^a   Munns, Craig F ^a  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

Chemotherapy; Osteonecrosis; Pediatric; Zoledronic acid

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; PREDNISOLONE; PROCARBAZINE; STEROID; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN; VINCRISTINE; ZOLEDRONIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTHRALGIA; ARTHROPLASTY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DENSITY; BONE NECROSIS; BONE TURNOVER; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; CHILDHOOD CANCER; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; CREATININE URINE LEVEL; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FANCONI ANEMIA; FEMALE; FLU LIKE SYNDROME; HODGKIN DISEASE; HUMAN; JOINT DESTRUCTION; JOINT RADIOGRAPHY; LARGE CELL LYMPHOMA; LEUKEMIA REMISSION; LUMBOSACRAL SPINE; LYMPHOBLASTOMA; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SIDE EFFECT; SIDEROBLASTIC ANEMIA; TREATMENT DURATION;

CHEMOTHERAPY; OSTEONECROSIS; PEDIATRIC; ZOLEDRONIC ACID;

ADOLESCENT; ARTHRALGIA; ARTHROPLASTY; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHILD; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LYMPHOMA; MALE; OSTEONECROSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84880372746     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24563     Document Type: Article

References (40)

1. McNeer JL, Nachman JB. The optimal use of steroids in paediatric acute lymphoblastic leukaemia: No easy answers. Br J Haematol 2010; 149:638-652.
2. te Winkel ML, Pieters R, Hop WCJ, et al. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol 2011; 29:4143-4150.
3. Sala A, Mattano LA, Jr., Barr RD. Osteonecrosis in children and adolescents with cancer-An adverse effect of systemic therapy. Eur J Cancer 2007; 43:683-689.
4. Patel B, Richards SM, Rowe JM, et al. High incidence of avascular necrosis in adolescents with acute lymphoblastic leukemia: A UKALL XII analysis. Leukemia 2008; 22:308-312.
5. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 2003; 101:3809-3817.
6. Burger B, Beier R, Zimmermann M, et al. Osteonecrosis: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)-Experiences from trial ALL-BFM 95. Pediatr Blood Cancer 2005; 44:220-225.
7. Mattano LA, Jr., Sather HN, Trigg ME, et al. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group. J Clin Oncol 2000; 18:3262-3272.
8. Vora A. Management of osteonecrosis in children and young adults with acute lymphoblastic leukaemia. Br J Haematol 2011; 155:549-560.
9. Relling MV, Yang W, Das S, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 2004; 22:3930-3936.
10. French D, Hamilton LH, Mattano LA, Jr., et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 2008; 111:4496-4499.
11. Asano T, Takahashi KA, Fujioka M, et al. Genetic analysis of steroid-induced osteonecrosis of the femoral head. J Orthop Sci 2003; 8:329-333.
12. Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992; 326:1473-1479.
13. Jager M, Zilkens C, Westhoff B, et al. Efficiency of iloprost treatment for chemotherapy-associated osteonecrosis after childhood cancer. Anticancer Res 2009; 29:3433-3440.
14. Li X, Cui Q, Kao C, et al. Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone 2003; 33:652-659.
15. Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop 2001; 386:173-178.
16. Laroche M, Jacquemier JM, Montane de la Roque P, et al. Nifedipine per os relieves the pain caused by osteonecrosis of the femur head. Rev Rhum Mal Osteoartic 1990; 57:669-670.
17. Agarwala S, Jain D, Joshi VR, et al. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford) 2005; 44:352-359.
18. Agarwala S, Shah S, Joshi VR. The use of alendronate in the treatment of avascular necrosis of the femoral head: Follow-up to eight years. J Bone Joint Surg Br 2009; 91:1013-1018.
19. Cardozo JB, Andrade DMS, Santiago MB. The use of bisphosphonate in the treatment of avascular necrosis: A systematic review. Clin Rheumatol 2008; 27:685-688.
20. Ramachandran M, Ward K, Brown RR, et al. Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. J Bone Joint Surg Am 2007; 89:1727-1734.
21. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9:2643-2658.
22. Kotecha RS, Powers N, Lee S-J, et al. Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). Pediatr Blood Cancer 2010; 54:934-940.
23. Nguyen T, Zacharin MR. Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia-Two-year outcomes. J Pediatr Endocrinol Metab 2006; 19:161-167.
24. Munns CF, Cowell CT. Prevention and treatment of osteoporosis in chronically ill children. J Musculoskelet Neuronal Interact 2005; 5:262-272.
25. Johannesen J, Briody J, McQuade M, et al. Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease. Bone 2009; 45:898-902.
26. Steinberg ME, Steinberg DR. Classification systems for osteonecrosis: An overview. Orthop Clin North Am 2004; 35:273-283.
27. Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111:4477-4489.
28. Parker C, Waters R, Leighton C, et al. Effect of Mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): An open-label randomised trial. Lancet 2010; 376:2009-2017.
29. Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: A report from the Children's Oncology Group. Blood 2011; 117:2596-2603.
30. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001; 97:3699-3706.
31. Gibson BES, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19:2130-2138.
32. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115:3206-3214.
33. McAvoy S, Baker KS, Mulrooney D, et al. Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010; 16:1231-1236.
34. Kawedia JD, Kaste SC, Pei D, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2011; 117:2340-2347.
35. Karimova EJ, Rai SN, Howard SC, et al. Femoral head osteonecrosis in pediatric and young adult patients with leukemia or lymphoma. J Clin Oncol 2007; 25:1525-1531.
36. Inaba H, Pui C-H. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol 2010; 11:1096-1106.
37. Mattano LA, Devidas M, Nachman JB, et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: Results from the CCG-1961 randomised cohort trial. Lancet Oncol 2012; 13:906-915.
38. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355:1572-1582.
39. Little DG, McDonald M, Sharpe IT, et al. Zoledronic acid improves femoral head sphericity in a rat model of perthes disease. J Orthop Res 2005; 23:862-868.
40. Little DG, Peat RA, McEvoy A, et al. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res 2003; 18:2016-2022.